So why haven't we investors seen the Phase K data?
The FDA
So why haven't we investors seen the Phase K data?
The FDA was presented it. Sure would help the SP.
"Cellceutix executives met this week with staff of the FDA Division of Oncology Products 1 to discuss the Kevetrin Phase 1 study data, as well as a proposed design of a planned Phase 2 trial in patients with ovarian cancer that have resistance to platinum-based therapy.
The FDA has agreed with Cellceutix's plan to initiate such a trial, and based upon the data from the Phase 1 trial, that the administration of Kevetrin doses at three times per week would be acceptable."
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
FlexCare: A New Era in Vehicle Protection Stellantis has introduced FlexCare as the new name for its vehicle service contracts and protection offerings. This innovative program replaces the former Mopar Vehicle Protection (MVP), bringing a familiar level of expert factory service and a diverse array of tailored vehicle protection products to customers. What is FlexCare?...
Continue Reading
Clean Juice Launches a Unique Promotion Clean Juice, the leading brand in organic juice bars, is dedicated to making nutritious choices more accessible to everyone. Their latest promotion allows customers to purchase a signature cold-pressed juice for just 20 cents with a $25 purchase. This initiative is designed to encourage a healthier lifestyle as we enter a new year...
Continue Reading
Economic Insights on Tariff Rollbacks Recent actions by President Trump to roll back specific tariffs aim to address the soaring prices affecting consumers, an approach labeled as a "remarkable admission" by notable economist Justin Wolfers. This move suggests that the administration recognizes the inflationary impact of its previous trade policies. Understanding Tariff...
Continue Reading
Introduction to New Credit Facilities Flow Traders Ltd. (Euronext: FLOW) has recently secured significant financial backing through a new credit facility, which includes a $200 million private credit and a $75 million revolving credit facility. This strategic move aims to enhance the firm's trading capital and fortify its global operations. Details of the Credit...
Continue Reading
New Perspectives on Community Development Finance In a compelling recent release, David Fukuzawa, Nancy O. Andrews, and Rebecca Steinitz introduced a fresh approach to community development finance. Their article, titled "A New Blueprint for Financing Community Development," published by Stanford Social Innovation Review, emphasizes the need for innovative financing...
Continue Reading
